menu search

FAMDF / Futura Medical primed for key year, says broker

Futura Medical primed for key year, says broker
Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s prelims were ‘broadly in with expectations', according to corporate broker Liberum, which repeated its ‘buy' recommendation and 121p a share price target for the stock. The results were notable in so much as they form a backdrop for the commercial push in 2023 for its key asset, Eroxon, a gel treatment for erectile dysfunction. Read More
Posted: Apr 5 2023, 04:03
Author Name: Proactive Investors
Views: 110810

FAMDF News  

Futura Medical wins new product award from Boots

By Proactive Investors
November 2, 2023

Futura Medical wins new product award from Boots

Futura Medical's Eroxon erectile dysfunction treatment won the "New Product of the Year, Healthcare" category at the Boots Supplier Awards 2023 follo more_horizontal

Futura Medical receives OTC sign-off in Mexico for ED gel

By Proactive Investors
October 25, 2023

Futura Medical receives OTC sign-off in Mexico for ED gel

Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in innovative sexual health products, has announced OTC Marketing Autho more_horizontal

Futura Medical ED drug roll continues apace

By Proactive Investors
October 19, 2023

Futura Medical ED drug roll continues apace

The roll-out of Futura Medical PLC (AIM:FUM, OTC:FAMDF)'s breakthrough erectile dysfunction gel continues apace with sales starting in the company's more_horizontal

Futura Medical shares up on patent news - interesting at these levels, says bank

By Proactive Investors
October 2, 2023

Futura Medical shares up on patent news - interesting at these levels, says bank

Futura Medical PLC (AIM:FUM, OTC:FAMDF), a pharmaceutical company specialising in sexual health products, has witnessed a 3% increase in its share pri more_horizontal

Futura Medical secures patent protection for ED gel out to 2040

By Proactive Investors
October 2, 2023

Futura Medical secures patent protection for ED gel out to 2040

Futura Medical PLC (AIM:FUM, OTC:FAMDF), the drug developer specialising in sexual health products, has secured a significant win with the European Pa more_horizontal

Futura Medical CEO James Barder discusses FDA approval, market share gains, and plans for Eroxon

By Proactive Investors
September 22, 2023

Futura Medical CEO James Barder discusses FDA approval, market share gains, and plans for Eroxon

In an exclusive with Proactive, James Barder, CEO of Futura Medical PLC (AIM:FUM, OTC:FAMDF), discusses the company's remarkable first half of the yea more_horizontal

Futura Medical: Pieces of the jigsaw falling into place, says investment bank

By Proactive Investors
September 18, 2023

Futura Medical: Pieces of the jigsaw falling into place, says investment bank

The past year has seen the pieces of the puzzle fall neatly into place for UK-based Futura Medical PLC (AIM:FUM, OTC:FAMDF), according to boutique inv more_horizontal

Futura Medical targets profitability as it sees early commercial traction for ED gel

By Proactive Investors
September 18, 2023

Futura Medical targets profitability as it sees early commercial traction for ED gel

Futura Medical PLC said it expects to be in a break-even position next year as the commercial traction grows around its erectile dysfunction gel Ero more_horizontal


Search within

Pages Search Results: